Cryptogenic new-onset refractory status epilepticus responded to anti-interleukin-6 treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neuroimmunology"
DOI: 10.1016/j.jneuroim.2021.577789
Abstract: OBJECTIVE The aim of this case report was to describe a potential anti-interleukin (IL)-6 treatment for cryptogenic new-onset refractory status epilepticus (C-NORSE). BACKGROUND Although an underlying immune-mediated pathogenesis is considered present in some C-NORSE cases,… read more here.
Keywords: anti interleukin; status; interleukin treatment; status epilepticus ... See more keywords
Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever
Sign Up to like & getrecommendations! Published in 2017 at "Modern Rheumatology"
DOI: 10.1080/14397595.2016.1194510
Abstract: Abstract Objective: To investigate the effect of anti-interleukin-1 (anti-IL-1) treatment on the frequency and severity of attacks and other disease-related clinical parameters and to evaluate the adverse effects associated with anti-IL-1 treatment in 26 patients… read more here.
Keywords: anti treatment; treatment; treatment patients; colchicine ... See more keywords
Perspectives on the pharmacological management of psoriasis in pediatric and adolescent patients
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2021.1911641
Abstract: ABSTRACT Introduction Psoriasis affects about 0.5% of children and adolescents, it has a high impact of social life. Management can be difficult. The beginning of the 21st century has been an interesting period for the… read more here.
Keywords: perspectives pharmacological; management; new topical; pharmacological management ... See more keywords
Effectiveness of anti‐interleukin‐23 therapy in psoriatic arthritis: A pilot prospective real‐world study
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.14663
Abstract: This study aimed to show the effectiveness of interleukin (IL)‐23 inhibitors in psoriatic arthritis (PsA) at weeks 12 and 24 in a real‐world setting. read more here.
Keywords: psoriatic arthritis; anti interleukin; real world; effectiveness anti ... See more keywords
Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Dermatology"
DOI: 10.1111/bjd.17779
Abstract: Major advances in psoriasis pathogenesis gave rise to development of new effective drugs for its treatment. Particularly, biologic drugs revolutionized disease management. TNF-α inhibitors represented the opening available biologic class since 2000. Thus, adverse cutaneous… read more here.
Keywords: eczematous eruption; interleukin treatment; treatment; eruption anti ... See more keywords
Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.14584
Abstract: Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin‐17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective. However, in those patients who failed one or… read more here.
Keywords: biologic drugs; biologic; patients failed; psoriasis ... See more keywords
Indirect comparison of anti‐interleukin 17 targeted biological treatments for moderate‐to‐severe psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13153
Abstract: Psoriasis is an inflammatory skin disease with an important disease burden worldwide and its treatment includes systemic therapies which have advanced over time to target specific immune cytokines such as interleukin‐17. The main objective of… read more here.
Keywords: interleukin targeted; targeted biological; comparison anti; indirect comparison ... See more keywords
THU0542 Anti-interleukin 1 therapy in FMF amyloidosis: a single center experience (case series)
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5397
Abstract: Background Recently there is increasing number of reports investigating the efficacy of anti-interleukin-1 (anti-IL1) therapy in AA-amyloidosis. Objectives Here we report our experience in IL-1 blockade in AA amyloidosis secondary to FMF. Methods Twenty nine… read more here.
Keywords: amyloidosis; therapy; thu0542 anti; anti interleukin ... See more keywords
Clinical utility of anti-interleukin 5 monoclonal therapy in asthma using a national, centralised, outcome-based system of drug access
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2022-001341
Abstract: Introduction Interleukin 5 (IL-5) inhibitors are an important therapeutic advance in the management of severe, refractory, eosinophilic asthma. However, their utilisation should be targeted to maximise their benefits. This study used multisite, centralised, national data… read more here.
Keywords: utility anti; asthma; therapy; monoclonal therapy ... See more keywords
Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Heart"
DOI: 10.1136/heartjnl-2020-318869
Abstract: Aims Corticosteroid-dependent and colchicine-resistant recurrent pericarditis (RP) is a challenging management problem, in which conventional anti-inflammatory therapy (nonsteroidal anti-inflammatory drugs, colchicine, corticosteroids) is unable to control the disease. Recent data suggest a potential role for… read more here.
Keywords: pericarditis; anti agents; recurrent pericarditis; anti interleukin ... See more keywords
Erratum to “Anti-Interleukin-22-Neutralizing Antibody Attenuates Angiotensin II-Induced Cardiac Hypertrophy in Mice”
Sign Up to like & getrecommendations! Published in 2018 at "Mediators of Inflammation"
DOI: 10.1155/2018/2586494
Abstract: [This corrects the article DOI: 10.1155/2017/5635929.]. read more here.
Keywords: antibody attenuates; attenuates angiotensin; neutralizing antibody; erratum anti ... See more keywords